SLC26A4 and hypertensive disorder: Further studies demonstrated that SLC26A4 mutations protect against the development of high blood pressure through enhanced urinary Na+/Cl− excretion, suggesting that SLC26A4 can serve as a potential target for anti-hypertensive drugs [75].